Systems for identifying clinically important microorganisms have evolved from conventional tubed and plated media, through miniaturizations of such tests and systems-based analyses, to rapid systems (9). These rapid systems-based analyses may improve the turnaround time in the clinical laboratory. The use of instrumentation to perform and interpret the results of rapid identification tests may assist the laboratory in performing cost-effective microbiological analyses. Recent studies suggest that rapid systems can decrease patient mortality rates and costs associated with hospitalization (4, 14).
Systems for identifying clinically important microorganisms have evolved from conventional tubed and plated media, through miniaturizations of such tests and systems-based analyses, to rapid systems (9) . These rapid systems-based analyses may improve the turnaround time in the clinical laboratory. The use of instrumentation to perform and interpret the results of rapid identification tests may assist the laboratory in performing cost-effective microbiological analyses. Recent studies suggest that rapid systems can decrease patient mortality rates and costs associated with hospitalization (4, 14) .
The MicroScan Rapid Gram-Negative Identification System (Dade MicroScan Inc., West Sacramento, Calif.) relies on the detection of preformed microbial enzymes. The identification panel comprises 36 biochemical tests and uses fluorometric technology to identify fermentative and nonfermentative, clinically relevant gram-negative taxa. Identification results are obtained in 2.5 h after incubation in the WalkAway automated test system. This system has recently been updated from the Type 2 Panel to the Rapid Gram-Negative Identification System Type 3 Panel (RNID3) to improve identification accuracy for common human clinical taxa, to remove the need for a mineral oil overlay for the decarboxylase tests, and to increase the shelf-life to 1 year at 2 to 8°C. New taxa, including Aeromonas jandaei, Aeromonas schubertii, Citrobacter braakii, Citrobacter farmeri, Citrobacter sedlakii, Citrobacter werkmanii, Citrobacter youngae, Enterobacter hormaechei, Escherichia coli O157:H7, Tatumella ptyseos, and Yersinia pestis were added to the database. The identification database for the revised panel was updated and now includes 119 taxa covering a total of 150 species, including 100 at the species level, 13 at the combinedspecies level, 4 at the genus level, and 2 at the combinedgenera level. Nomenclature changes were incorporated for 24 species. Modifications were made to improve the identification of species currently included in the database.
These improvements were made by modifying the biochemical tests in the panel while maintaining the same 36-test-well format. Specifically, 10 substrates present on the RNID2 were replaced by 10 new tests. The revised RNID3 continues to use three distinct types of tests: enzyme tests, tests with fluorescent pH indicators, and a fluorescence quenching test to allow for identification in the absence of growth. These tests have been described in detail previously (8) .
The present multicenter study was performed to evaluate the overall accuracy of RNID3 for a wide range of gramnegative isolates. This evaluation was performed in three phases: the efficacy, challenge, and reproducibility testing phases. Efficacy testing examined the results for common species encountered in the clinical laboratory. The results were compared with those obtained with the API 20E system (bioMérieux Vitek, Hazelwood, Mo.) or by the conventional tube method. Challenge testing was conducted with stock isolates representing the new species added to the database as well as closely related or similar taxa. Reproducibility testing examined the ability of RNID3 to provide consistent and reproducible isolate identification and individual test results when the panel was used by multiple laboratories.
MATERIALS AND METHODS
Test sites. Efficacy testing was performed at the Medical Center of the University of California at Los Angeles (UCLA) and the Centers for Disease Control and Prevention (CDC). Challenge testing was performed by CDC and the Microbial Disease Laboratory, California State Department of Health Services. Reproducibility testing was performed at UCLA, CDC, and Dade MicroScan Inc. Testing was performed by up to four technologists at each site.
Isolate preparation. The fresh bacterial isolates tested were less than or equal to 3 days old and had not previously been frozen. Stock strains were subcultured twice onto Trypticase soy agar with 5% sheep blood (BAP) to ensure purity and viability. Prior to testing, all isolates were grown on a MacConkey agar plate with lactose and crystal violet, and the plates were incubated for 18 to 24 h in an incubator without CO 2 at 35°C. Bacteria that did not grow on MacConkey agar were grown on BAP for 18 to 24 hours in an incubator without CO 2 at 35°C.
RNID3. RNID3 was inoculated by following the manufacturer's instructions. In brief, organisms from well-isolated colonies were suspended in saline with Pluronic (BASF, Parsippany, N.J.) to a suspension with a turbidity equivalent to that of a 0.5 McFarland standard. Panels were inoculated with a Renok Rehydrator Inoculator, covered, and placed in the WalkAway system (incubation at 35°C). Identification results were obtained in 2.5 h. The RNID3 identification criteria for "species agreement-high probability" was that the unknown species was identified at a species (or combined-species) level with a probability of Ն85% and the identification agreed with the reference identification. If the unknown species was not identified at a species level with a probability of Ն85% but the correct species appeared as one of the top three possible identifications at a low probability, it was termed "species agreement-low probability." All RNID3 identifications in this group were confirmed with the additional tests recommended by the system. "Incorrect identifications" did not meet any of the criteria given above. "Very rare biotype" was used if the results for the unknown showed too many deviations from the expected results. In addition, the term "genus/group agreement-high probability" was used if the unknown was not identified at a species level with a probability of Ն85%, but the sum of the probabilities for members of the correct genus or group was Ն85%.
API 20E system. The API 20E system was inoculated according to the manufacturer's instructions. This system provides bacterial identifications with 1 of 10 possible comments. Unknown identifications termed "excellent identification," "very good identification," and "acceptable identification" were considered correct with no additional testing. The manufacturer recommends that all other descriptions, including a "good likelihood, low selectivity" identification, be considered low probabilities and that additional testing be performed before a final identification can be attained.
Quality control. Eight quality control strains plus a saline blank were tested on the RNID3 during each phase of the study. Each of the participating laboratories performed replicate tests with each of the eight quality control strains against the panel identification tests for a total of 31 test points per isolate per identification substrate tested. The strains were Acinetobacter baumannii ATCC 49139, Aeromonas hydrophila ATCC 49140, Enterobacter aerogenes ATCC 51697, Escherichia coli ATCC 25922, Klebsiella oxytoca ATCC 49131, Pseudomonas aeruginosa ATCC 27853, Proteus vulgaris ATCC 49132, and Shewanella putrefaciens ATCC 49138. Quality control for the API 20E system was performed prior to efficacy testing and with each new lot of API 20E strips used. Testing was performed according to the manufacturer's instructions.
Efficacy testing. A total of 405 fresh and stock gram-negative isolates comprising 54 species were tested. One clinical site (UCLA) tested 206 fresh isolates received at typical representative ratios encountered in the laboratory. An additional 139 fresh isolates obtained from Atlanta area hospitals and 60 stock isolates were tested at a second site (CDC). Organisms were tested concurrently on RNID3 and with the API 20E system. During efficacy testing, the identification results from RNID3 were compared with the identification results from the API 20E system. When identifications by both methods were in agreement with a high probability, the data were considered final. When test results differed or were low-probability identifications, the isolate was retested with both systems. In some cases, isolates were not repeat tested but were sent directly to CDC for arbitration of the results by conventional tube methods (5) . If after repeat testing identifications from both RNID3 and the API 20E system were in agreement with a high probability, the data were considered final and the repeat result was used. Isolates with identifications that did not agree or that were considered low probability even after repeat testing were sent to CDC for arbitration of the results by conventional tube methods. The conventional tube method identification was used as the final reference identification for these strains.
Challenge testing. A total of 247 stock gram-negative isolates comprising 39 species were tested at CDC and the Microbial Disease Laboratory, California State Department of Health Services. Each site selected isolates representing the new species added to the database and closely related or similar taxa. Each site determined bacterial identifications using an appropriate reference method (5) prior to the start of the challenge testing. Identifications from RNID3 were compared with the expected identifications. When the identification by RNID3 was in agreement to the species level at high probability with the conventional tube method identification, the data were considered final. When the test results differed or the RNID3 identification was species agreement-low probability, repeat testing was performed. The identification from the repeat test replaced the initial identification in the data analysis.
Reproducibility testing. Fifteen gram-negative organisms were selected for testing on RNID3. 
RESULTS

Quality control.
Efficacy testing. The results of efficacy testing for the 405 isolates on RNID3 are presented in Table 1 . A total of 379 of 405 strains (93.6%) were in species agreement-high probability with the API 20E system or conventional tube test result. An additional 14 of 405 strains (3.5%) were in species agreementlow probability. Of these, 5 of 14 could be further categorized as genus/group agreement-high probability. Additional tests, as recommended by MicroScan, were performed for these 14 bacteria, and 13 of 14 identifications were confirmed. The one isolate whose identification was not confirmed was a VogesProskauer-negative Enterobacter cloacae isolate which was misidentified as a Kluyvera sp. An incorrect identification was obtained for 11 of 405 (2.7%) of the isolates tested. The 11 misidentified isolates (the RNID3 identification is given in in parentheses) were Citrobacter genomospecies 10 (Citrobacter braakii, Citrobacter freundii, Citrobacter sedlakii), Edwardsiella tarda (Yersinia ruckeri), Enterobacter agglomerans (Enterobacter amnigenus), Kluyvera cryocrescens (Moraxella sp.), Proteus mirabilis (Bergeyella zoohelcum), Pseudomonas alcaligenes (Oligella urethralis), Salmonella gallinarum (Shigella sp.), Serratia liquefaciens (Serratia odorifera), Serratia marcescens (Serratia liquefaciens), Serratia odorifera (Yersinia pseudotuberculosis), and Serratia rubidaea (Yersinia enterocolitica). Six of these 11 isolates that were misidentified by RNID3 were also misidentified by the API 20E system in comparison with the identifications by the conventional tube method. Finally, 1 of 405 strains (0.2%; Serratia fonticola) gave an identification of a very rare biotype by RNID3. Thus, the combined percentage of correct identifications with RNID3 was 392 of 405, or 96.8% of the isolates used for efficacy testing.
Challenge testing. The results of the challenge tests with stock isolates on RNID3 are presented in Table 2 . Identification results for a total of 201 of 247 isolates (81.4%) were in species agreement-high probability with the reference identification. Identification results for an additional 23 of 247 isolates (9.3%) were in species agreement-low probability and additional tests were required. Those tests were performed as recommended by MicroScan and confirmed 20 of the 23 lowprobability identifications. The three isolates whose identities were not confirmed were a lactose-negative Escherichia coli strain (identified as a Shigella sp.), a sucrose-negative Aeromonas trota strain (identified as Aeromonas schubertii), and one isolate for which the recommended oxidase test did not distinguish between the correct identification of Moraxella sp. and CDC Group M6, CDC Group EF-4B, or Neisseria weaveri. Thus, the combined percentage of correct identifications with RNID3 was 89.5%, or 221 of 247 of the stock challenge isolates. Misidentifications were seen for 23 isolates. The 23 isolates which were misidentified (the RNID3 identification is given in parentheses) were Reproducibility testing. The reproducibility of RNID3 was analyzed in terms of both overall identification and individual test or substrate reproducibilities. There were 31 possible biotype results for each of the 15 isolates, or 465 possible identification results. RNID3 gave the correct species with a highprobability result for 452 of 465 isolates (97.2%). There were 13 of 465 (2.8%) biotype results which resulted in low-probability identifications. Twelve of these 13 provided identifications which gave correct species agreement with a low probability. These were 4 of 31 results for Aeromonas hydrophila, The results for individual test or substrate reproducibility are presented in Table 3 . The overall test reproducibility was 99.9% (14,373 of 14,384) . The reproducibilities for all tests ranged from 98.4 to 100%. The result for each individual isolate-test combination was in agreement with the expected result for Ͼ97% of the test points with one exception. The decarboxylase base test gave a 90.3% agreement with Proteus vulgaris due to 3 negative test results of an expected 31 positive results.
DISCUSSION
This multicenter study used both fresh and stock clinical isolates in the efficacy phase, as well as a challenge set of stock Other less frequently encountered groups such as a Yokenella sp. and Cedecea spp. were not tested in this study. The database development study (2) indicated 94.7% (18 of 19) and 98.3% (59 of 60) high-probability agreements with the reference methods for these two species, respectively. Further studies aimed at confirming the accuracy of RNID3 in identifying these and other less frequently encountered genera are in progress.
The reproducibility of the system was excellent, with overall identification reproducibility being 99.8% and overall test reproducibility being 99.9%. The level of agreement among laboratories was exceedingly high and included 97.2% identification reproducibility at a high probability.
In summary, we have shown that RNID3 gives accurate and highly reproducible results in a multiple-laboratory evaluation. The substantial increase in the accuracy of identification by RNID3 combined with the addition of data covering new taxa provides a rapid and accurate system for the identification of clinically significant gram-negative bacteria.
